Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Regulations
  • Topics
  • Trading Ideas

WW International Shares Jump On BCBS Michigan’s Revised Authorization For Wegovy, Other Weight Loss Drugs

By AJ Fabino
Yesterday, 4:25 PM
Shares of WW International Inc (NASDAQ:WW) spiked as much as 15% on Friday after Blue Cross Blue Shield…

NVO

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • News

On September 19, Reshape Lifesciences Entered Into Exclusive License Agreement With Biorad Medysis Pvt. Ltd.;

By Benzinga Newsdesk
Yesterday, 4:06 PM
- SEC Filing On September 19, 2023, ReShape Lifesciences Inc. (the "Company") entered into an Exclusive License Agreement (the "License Agreement") with Biorad Medysis Pvt. Ltd. ("Biorad"), pursuant to which

RSLS

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Initiation
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Price Target
  • Trading Ideas

Optimism Surrounds Cancer Focused Ikena Oncology, Analyst Initiates With Outperform

By Vandana Singh
Yesterday, 2:16 PM
Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community. 

IKNA

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

Why Is Seagen Stock Trading Higher Today?

By Vandana Singh
Yesterday, 11:05 AM
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: 

ALPMF

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer

By Vandana Singh
Yesterday, 10:21 AM
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: 

ESALF

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Bristol Myers’ Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study

By Vandana Singh
Yesterday, 10:18 AM
Bristol Myers Squibb & Co (NYSE: BMY) announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant (before surgery) Opdivo (nivolumab) with chemotherapy followed by surgery and 

BMY

Read More
4 minute read
  • Biotech
  • General
  • Global
  • News

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze For The Treatment Of Acute Lymphoblastic Leukemia And Lymphoblastic Lymphoma

By Benzinga Newsdesk
Yesterday, 9:01 AM
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Jazz Pharmaceuticals plc (NASDAQ:JAZZ), ("Jazz") has been granted marketing authorization by the European Commission (EC) for Enrylaze®

JAZZ

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Tech

From Years to Months: How AI is Shaping the Landscape of Clinical Trials

By Vandana Singh
Yesterday, 7:49 AM
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These human studies, crucial to drug development, can take years and accrue costs in the billions.

AMGN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Better Than Chemotherapy – AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting

By Vandana Singh
Yesterday, 7:46 AM
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC: 

AZN

Read More
2 minute read
  • Cannabis
  • FDA
  • Markets
  • News
  • Penny Stocks
  • Psychedelics

Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression

By Lara Goldstein
September 21, 10:04 PM
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.) 

CYBN

Posts navigation

1 2 … 507 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service